Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUREMA: Radical Cure for Malaria in Guyanese Shield
NCT05540470Completed
- Sponsor
- Centre Hospitalier de Cayenne
- Start
- Sep 2022
- Primary completion
- Mar 2025
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 2
01
Overview
Open-label trial of tafenoquine in malaria (3 arms), sponsored by Centre Hospitalier de Cayenne. Primary endpoints: Effectiveness focus at 3 years and Implementation focus at 3 years. Started Sep 2022; status: completed.
02
Drugs
tafenoquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05540470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05540470.